{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:23:26Z","timestamp":1763018606071},"reference-count":25,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2023.14056","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T06:11:54Z","timestamp":1695103914000},"source":"Crossref","is-referenced-by-count":1,"title":["Comparison of the outcomes of patients with primary central nervous system lymphoma between the neurosurgery and hematology\/oncology departments based on the relative dose intensity of methotrexate"],"prefix":"10.3892","volume":"26","author":[{"given":"Hiroki","family":"Hosoi","sequence":"first","affiliation":[{"name":"Department of Hematology\/Oncology, Wakayama Medical University, Wakayama 641\u20118509, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Okamura","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Wakayama Medical University, Wakayama 641\u20118509, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Fukai","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Wakayama Medical University, Wakayama 641\u20118509, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikazu","family":"Hori","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Wakayama Medical University, Wakayama 641\u20118509, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shogo","family":"Murata","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Wakayama Medical University, Wakayama 641\u20118509, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki","family":"Mushino","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Wakayama Medical University, Wakayama 641\u20118509, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Nakao","sequence":"additional","affiliation":[{"name":"Department of Neurological Surgery, Wakayama Medical University, Wakayama 641\u20118509, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Sonoki","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Wakayama Medical University, Wakayama 641\u20118509, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2023,9,19]]},"reference":[{"key":"key20231018120927_b1-ol-26-5-14056","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1182\/blood.2020008377","article-title":"Primary central nervous system lymphoma","volume":"140","author":"Schaff","year":"2022","journal-title":"Blood"},{"key":"key20231018120927_b2-ol-26-5-14056","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1182\/asheducation-2010.1.21","article-title":"Adolescents and young adults with acute lymphoblastic leukemia","volume":"2010","author":"Stock","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"key20231018120927_b3-ol-26-5-14056","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00277-010-0956-7","article-title":"Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma","volume":"89","author":"Hirakawa","year":"2010","journal-title":"Ann Hematol"},{"key":"key20231018120927_b4-ol-26-5-14056","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1182\/bloodadvances.2021004665","article-title":"Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: A systematic review","volume":"5","author":"Bataillard","year":"2021","journal-title":"Blood Adv"},{"key":"key20231018120927_b5-ol-26-5-14056","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1007\/s00277-018-3468-5","article-title":"Impact of front line relative dose intensity for methotrexate and comorbidities in immunocompetent elderly patients with primary central nervous system lymphoma","volume":"97","author":"Farhi","year":"2018","journal-title":"Ann Hematol"},{"key":"key20231018120927_b6-ol-26-5-14056","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1200\/JCO.2003.09.139","article-title":"Prognostic scoring system for primary CNS lymphomas: The international Extranodal lymphoma study group experience","volume":"21","author":"Ferreri","year":"2003","journal-title":"J Clin Oncol"},{"key":"key20231018120927_b7-ol-26-5-14056","doi-asserted-by":"publisher","first-page":"5711","DOI":"10.1200\/JCO.2006.08.2941","article-title":"Primary central nervous system lymphoma: The Memorial Sloan-Kettering cancer center prognostic model","volume":"24","author":"Abrey","year":"2006","journal-title":"J Clin Oncol"},{"key":"key20231018120927_b8-ol-26-5-14056","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1200\/JCO.2013.50.4910","article-title":"Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: Final results and long-term outcome","volume":"31","author":"Morris","year":"2013","journal-title":"J Clin Oncol"},{"key":"key20231018120927_b9-ol-26-5-14056","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","article-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","author":"Abrey","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20231018120927_b10-ol-26-5-14056","doi-asserted-by":"publisher","first-page":"101396","DOI":"10.1016\/j.jgo.2022.10.011","article-title":"An evaluation based on relative treatment intensity in older patients treated with reduced-dose R-THP-COP therapy for diffuse large B-cell lymphoma: A multicenter retrospective cohort study","volume":"14","author":"Hiroi","year":"2023","journal-title":"J Geriatr Oncol"},{"key":"key20231018120927_b11-ol-26-5-14056","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"key20231018120927_b12-ol-26-5-14056","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s00280-019-03914-2","article-title":"Pharmacokinetics of thiotepa in high-dose regimens for autologous hematopoietic stem cell transplant in Japanese patients with pediatric tumors or adult lymphoma","volume":"84","author":"Kondo","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20231018120927_b13-ol-26-5-14056","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/s00277-021-04744-0","article-title":"Tirabrutinib maintenance therapy for a patient with high-dose methotrexate-ineligible primary central nervous system lymphoma","volume":"101","author":"Okamura","year":"2022","journal-title":"Ann Hematol"},{"key":"key20231018120927_b14-ol-26-5-14056","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1200\/JCO.2003.02.053","article-title":"Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials","volume":"21","author":"Boissel","year":"2003","journal-title":"J Clin Oncol"},{"key":"key20231018120927_b15-ol-26-5-14056","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1182\/blood-2008-01-130237","article-title":"Cancer and Leukemia Group B studies: What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of children's cancer group and cancer and leukemia group B studies","volume":"112","author":"Stock","year":"2008","journal-title":"Blood"},{"key":"key20231018120927_b16-ol-26-5-14056","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1200\/JCO.2003.11.116","article-title":"Differences in outcome in adolescents with acute lymphoblastic leukemia: A consequence of better regimens?","volume":"21","author":"Schiffer","year":"2003","journal-title":"Better doctors? Both? J Clin Oncol"},{"key":"key20231018120927_b17-ol-26-5-14056","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1093\/oxfordjournals.annonc.a058619","article-title":"Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: Application to LNH-87 protocol. The GELA (Groupe d'Etude des Lymphomes de l'Adulte)","volume":"4","author":"Lepage","year":"1993","journal-title":"Ann Oncol"},{"key":"key20231018120927_b18-ol-26-5-14056","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","article-title":"Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: Results of the first randomisation of the international Extranodal lymphoma study group-32 (IELSG32) phase 2 trial","volume":"3","author":"Ferreri","year":"2016","journal-title":"Lancet Haematol"},{"key":"key20231018120927_b19-ol-26-5-14056","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1093\/annonc\/mdv076","article-title":"First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)-a systematic review and individual patient data meta-analysis","volume":"26","author":"Kasenda","year":"2015","journal-title":"Ann Oncol"},{"key":"key20231018120927_b20-ol-26-5-14056","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1016\/S1470-2045(15)00076-5","article-title":"Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: Guidelines from the European association for neuro-oncology","volume":"16","author":"Hoang-Xuan","year":"2015","journal-title":"Lancet Oncol"},{"key":"key20231018120927_b21-ol-26-5-14056","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/S2352-3026(17)30174-6","article-title":"Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: Results of the second randomisation of the international Extranodal lymphoma study group-32 phase 2 trial","volume":"4","author":"Ferreri","year":"2017","journal-title":"Lancet Haematol"},{"key":"key20231018120927_b22-ol-26-5-14056","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1200\/JCO.18.00306","article-title":"Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: Results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study","volume":"37","author":"Houillier","year":"2019","journal-title":"J Clin Oncol"},{"key":"key20231018120927_b23-ol-26-5-14056","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/jjco\/hyaa073","article-title":"Consecutive single-institution case series of primary central nervous system lymphoma treated by R-MPV or high-dose methotrexate monotherapy","volume":"50","author":"Sasaki","year":"2020","journal-title":"Jpn J Clin Oncol"},{"key":"key20231018120927_b24-ol-26-5-14056","first-page":"183","article-title":"Primary central nervous system lymphoma: A real-world comparison of therapy access and outcomes by hospital setting","volume":"9","author":"Patel","year":"2022","journal-title":"Neurooncol Pract"},{"key":"key20231018120927_b25-ol-26-5-14056","doi-asserted-by":"publisher","first-page":"100213","DOI":"10.1016\/j.esmoop.2021.100213","article-title":"How we treat primary central nervous system lymphoma","volume":"6","author":"Calimeri","year":"2021","journal-title":"ESMO Open"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T09:10:31Z","timestamp":1697620231000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2023.14056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,19]]},"references-count":25,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,9,19]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2023.14056","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,19]]},"article-number":"469"}}